Fig. 4.

Dose-dependent inhibition of B cell receptor-signaling in CLL cells by Hizentra. Purified CLL cells were stimulated with anti-IgM antibodies (10 ng/mL) or the TLR7-agonist Resiquimod (1 μg/ml) in the presence and absence of Hizentra at the indicated concentrations. After 4 h, CD83 expression was measured by flow cytometry. A. An example for one patient sample is shown in the top histograms, with the numbers indicating mean fluorescence intensity (MFI) of CD83-staining. B,C. The graphs show results of IgM-cross-linking for 25 different patient samples. Individual values for each treatment condition are shown on the left (B) with averages and standard deviations on the right (C). Hizentra at 15 g/L significantly (p < .01) decreased BCR-activation in contrast to 4 g/L. D–F. After 30 min, phospho- and total AKT, phospho-PLCγ, and β-actin in 9 additional samples were measured by immunoblotting and quantified by densitometry. Representative immunoblots are shown (D). Relative densitometry values for each condition are shown with the lines indicating results from individual patient samples (E). Averages and standard errors are shown in the graphs (F). *, p < .05.